Ocean Biomedical, Inc. (OCEA)

Ocean Biomedical, Inc. (OCEA) — VMCI valuation read

OCEA screens at VMCI 24/100, a 26-point gap below the Healthcare sector median (50). For a mid-cap Ocean Biomedical, Inc. share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

OCEA has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: OCEA trades at 22.0x earnings, 22% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp, the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 0.2x leaves covenant headroom, which sets the rate-cycle exposure for Ocean Biomedical, Inc..

OCEA rose 2.8% over the trailing 7 days, with a +1.8% read on a 30-day basis.